Concepedia

Jianyang Weng

JW

Statistics

Publications

2

Citations

169

H-Index

2

Active since

2014

Affiliations

Janssen (United States)(Current)

Jianyang Weng is an author at Janssen (United States) specializing in drug discovery, pharmacology, and structure-activity relationships.

Publications per year

2014–2019

2

Publications

2

Discovery of (<i>S</i>)-1-(1-(Imidazo[1,2-<i>a</i>]pyridin-6-yl)ethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Hong Jia, Guangxiu Dai, Jianyang Weng et al. · Journal of Medicinal Chemistry · 2014 · 134 citations · Full text

, , +9

Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ–PI3Kδ Dual Inhibitors

Hong Peng Jia, Guangxiu Dai, Wei-guo Su et al. · Journal of Medicinal Chemistry · 2019 · 35 citations · Full text

, , +17

1–2 of 2